Article info

Download PDFPDF
Concise report
Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1)

Authors

  1. Correspondence to Professor Vibeke Strand, Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto CA 94034, USA; vstrand{at}stanford.edu
View Full Text

Citation

Strand V, Mease P, Gossec L on behalf of the FUTURE 1 study group, et al
Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1)

Publication history

  • Received December 18, 2015
  • Revised March 4, 2016
  • Accepted April 14, 2016
  • First published May 11, 2016.
Online issue publication 
October 31, 2019

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.